Clinical Trial Update: Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating autologous CMV-specific cytotoxic T cells with temozolomide in glioblastoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Positive Brain Neoplasms
• Glioblastoma
• Malignant Glioma

Drugs mentioned

• Autologous CMV-specific cytotoxic T cells (CMV-specific cytotoxic T cells)
• Temozolomide (Temozolomide)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Cytomegalovirus Positive, Glioblastoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-06-18